2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2925

Programmed Cell Death (PD)-1 May Play a Significant Role in the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 2926

Rorc Positive Th17, Th17/Th1, and Th17.1 Cells from the Blood of Treatment NaïVe RA Patients Differ in IL-17A but Are All Pathogenic When Co-Cultured with RA Synovial Fibroblasts
Abstract Number: 2927

Mechanisms Regulating the Loss of Tregs in CD11c-Flip-KO Mice That Contribute to the Spontaneous Development of Inflammatory Arthritis
Abstract Number: 2928

Hypomethylation of an Intragenic Alternative Promoter Contributes to Impaired Treg Function in Rheumatoid Arthritis By Transcriptional Interference with Expression of the Treg-Specific Protein, Glycoprotein a Repetitions Predominant (GARP)
Abstract Number: 2929

The Baseline Th17 Lymphocytes Level Is a Predictive Marker of Good Response to Biologics in Rheumatoid Arthritis
Abstract Number: 2930

Specific Metabolic and Functional Changes in Peripheral CD8+ T Cells Specifically Distinguish RA from PSA and SPA
Abstract Number: 2931

Endogenous Nur77 Is a Specific Indicator of Antigen Receptor Signaling in Human T and B Cells
Abstract Number: 2932

HLA-DR3 Restricted Response to Lupus-Related Auto-Antigen Smd: Autoreactive T Cells Are Inherent in Normal Immune Repertoires
Abstract Number: 2933

HLA-DR3 Restricted T Cell Response to Smd and Ro60 Reveals Multiple Cross-Reactive Intra- and Inter-Molecular T Cell Epitopes: Unique Antigenic Structures of Lupus-Related Auto-Antigens and the Basis for B Cell Epitope Spreading
Abstract Number: 2934

Clinical Assessment of the Monoclonal Anitbody, PRX003, a Potential Novel Treatment for Th17-Mediated Inflammatory Disease
Abstract Number: 2935

Activation Status of Mucosal-Associated Invariant T Cells Sensitively Reflects Disease Activity of Systemic Lupus Erythematosus
Abstract Number: 2936

All-Trans Retinoic Acid Stabilizes Natural T Regulatory Cells Isolated from Patients with Systemic Lupus Erythematosus Under Inflammatory Conditions
Abstract Number: 2937

Regulation of Follicular Helper T (TFH) Cells By ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Abstract Number: 2938

U4ATAC Mutation Is Associated with an Immune Dysregulation Syndrome Characterized By Primary Immunodeficiency, Short Stature and Polyglandular Endocrinopathy
Abstract Number: 2939

Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].